New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

FDA Restricts J&J COVID-19 Vaccine

A possible risk of a blood clotting condition has led the agency to apply strict limits on the single-shot vaccine.

Screen Shot 2022 04 18 At 2 48 25 Pm
Getty Images

A recent CNN Health article discussed the recent limitations placed on Johnson & Johnson’s COVID-19 vaccine. Last week, the FDA dialed back its emergency use authorization for people 18 and older. A statement released by the agency cited a possible risk of thrombosis with thrombocytopenia syndrome, a rare blood clotting condition, after vaccination. Despite this, the FDA believes the benefits of the J&J vaccine still outweigh the risk for certain people, including:

  • Those who had a severe allergic reaction to an mRNA vaccine such as those from Pfizer/BioNTech or Moderna
  • Those with personal concerns about the mRNA vaccines who would remain unvaccinated without the J&J vaccine
  • Those with limited access to mRNA Covid-19 vaccines

Thus far, nearly 19 million doses of the vaccine have been administered in the U.S., accounting for 7.7% of fully vaccinated people.

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts